Edwards Lifesciences Cash Flow Statement
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edwards Lifesciences free cash flow
In fiscal 2025, Edwards Lifesciences generated $1.60 billion of operating cash flow and spent $260.2 million on capital expenditures. That left free cash flow of $1.33 billion, a free-cash-flow margin of 22.0% of revenue. Free cash flow was up 360.5% from the prior year's $289.9 million.
Edwards Lifesciences returned $893.4 million to shareholders through share repurchases, equal to 67% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Edwards Lifesciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.07B | 4.17B | 1.40B | 1.52B | 1.50B | 823.40M | 1.05B | 722.20M | 583.60M | 569.50M |
| Net Income growth (YoY) | -74.35% | +197.96% | -8.05% | +1.25% | +82.55% | -21.35% | +44.96% | +23.75% | +2.48% | +15.07% |
| Depreciation & Amortization | 156.60M | 155.20M | 144.90M | 139.60M | 134.80M | 107.20M | 89.30M | 77.40M | 81.90M | 71.20M |
| Stock-Based Compensation | 158.10M | 162.30M | 139.40M | 126.80M | 109.30M | 92.60M | 81.30M | 71.00M | 61.60M | 56.90M |
| Change in Working Capital | 399.10M | -22.70M | -366.00M | -318.80M | 131.00M | -191.70M | -83.70M | -66.30M | -67.90M | -60.90M |
| Operating Cash Flow | 1.60B | 542.30M | 895.80M | 1.22B | 1.73B | 1.05B | 1.18B | 926.70M | 1.00B | 704.40M |
| Capital Expenditures | -260.20M | -252.40M | -253.00M | -244.60M | -325.80M | -407.00M | -254.40M | -238.70M | -168.10M | -176.10M |
| Investing Cash Flow | -712.90M | 2.31B | 173.80M | 252.30M | -1.72B | -531.10M | -595.80M | 76.70M | -647.20M | -211.70M |
| Share Repurchases | -893.40M | -1.16B | -879.60M | -1.73B | -512.80M | -625.40M | -263.30M | -795.50M | -763.30M | -662.30M |
| Debt Issued | — | — | 0 | 0 | 5.20M | 16.20M | 18.90M | 688.00M | 994.70M | 253.50M |
| Debt Repaid | — | — | -300.00K | -200.00K | -7.00M | -17.00M | -28.90M | -1.13B | -818.40M | -31.40M |
| Financing Cash Flow | -956.80M | -983.00M | -711.00M | -1.58B | -356.30M | -486.90M | -115.60M | -1.10B | -473.20M | -268.50M |
| Net Change in Cash | -119.30M | 1.91B | 375.40M | -94.80M | -332.80M | 15.80M | 468.50M | -104.30M | -111.80M | 211.70M |
| Free Cash Flow | 1.33B | 289.90M | 642.80M | 973.60M | 1.41B | 647.30M | 928.50M | 688.00M | 832.60M | 528.30M |
This table shows 10 annual periods of Edwards Lifesciences's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EW's reporting calendar. What is a cash flow statement?